enzastaurin has been researched along with Lymphoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Almasan, A; Bodo, J; Hsi, ED; Maciejewski, JP; Sedlak, J | 1 |
| Ogura, M | 1 |
1 trial(s) available for enzastaurin and Lymphoma
| Article | Year |
|---|---|
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
1 other study(ies) available for enzastaurin and Lymphoma
| Article | Year |
|---|---|
HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fluorescent Antibody Technique; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lymphoma; Sulfides; Tumor Suppressor Protein p53; Valproic Acid; Vorinostat | 2011 |